Clinical trials: Allo-SCT Patients
Allo-SCT Patients, Adult Allo-SCT Survivor
Web-based Patient Education Program to Manage Side Effects of Allogeneic Stem Cell Transplant
The purpose of this study is to develop an interactive web-based patient education program to help educate patients about the increased risk of MS and its cardiac risk factors following allo-SCT and to inform and motivate…
- Trial name
- NCT02812082
- Testing
- web-based patient education, questionnaire
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Treatment, Stem Cell Transplantation
Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study
This study is an open-label, multicentric, exploratory, single arm, phase II study of adults who are either more than 60 years old, or are unfit for intensive chemotherapy and allo SCT.
- Trial name
- LAL1408 (NCT01025505)
- Testing
- Nilotinib, Imatinib
- Where
- 35 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Hematologic Malignancies
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets
In the transplant community, there is debate regarding the most appropriate food services for stem cell transplant patients. Recommendations regarding the use of low bacterial diets have been based on theoretical concepts of…
- Trial name
- NCT01687231
- Testing
- Non-neutropenic Diet
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Duke University
Allogeneic Stem Cell Transplantation in Elderly Patients
Allogeneic Stem Cell Transplantation (ALLO-SCT) in Elderly: 17-years Retrospective GITMO Survey
The age of patients' population is increasing every year, as the life expectancy. Thus, the incidence and prevalence of hematological cancers is increasing.
- Trial name
- NCT04469985
- Where
- Italy
- Volunteers
- 2,061 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Quality of Life, Patient Reported Outcome (PRO)
Patient-Reported Outcomes in Allogeneic Stem Cell Transplantation and CAR-T Therapy
3.1. Overview Prospective, multicenter, observational cohort study comparing short-term PROs measured with the HM-PRO between two exposure groups: patients undergoing allogeneic stem cell transplantation (allo-SCT) and patients…
- Conditions
- Quality of Life, Patient Reported Outcome (PRO), Allogeneic Blood and Marrow Transplantation (BMT), CAR T Cell Therapy
- Trial name
- QOL-ONE PRO-CT (NCT07289087)
- Volunteers
- 162 people
- Sponsor
- Associazione Qol-one
Acute Myeloid Leukaemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia
This is a prospective, multicenter, phase II, open-label, non-randomized clinical trial designed to evaluate the safety and efficacy of the Fludarabine plus Treosulfan 14 g/m² (FT14) conditioning regimen for allogeneic stem cell…
- Trial name
- FT14 (NCT07232953)
- Testing
- Fludarabine + Treosulfan
- Where
- 13 sites in Italy
- Volunteers
- 82 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Acute Lymphocytic Leukemia
Allo CART-19 Protocol
The primary objective is to determine the safety and survival of the redirected allogeneic T cells transduced with the anti-CD19 lentiviral vector (referred to as CART-19 cells).
- Trial name
- NCT01551043
- Testing
- CART-19
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pennsylvania
Hematologic Diseases, Stem Cell Transplant Complications
ALLO-SCT in Elderly Patients With Hematological Disease
Retrospective, observational, multicentre, spontaneous, non-interventional study This study will evaluate all consecutive patients older than 60 years who received hematopoietic stem cell transplantation (HSCT) between 1st…
- Trial name
- NCT04386928
- Where
- 29 sites in Italy
- Volunteers
- 1,996 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Hematologic Malignancies
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
This is an open-label, dose escalation Phase I study to evaluate the tolerability and efficacy of single agent of Nivolumab as maintenance treatment to prevent relapse in patients with hematologic malignancies after allogeneic…
- Trial name
- NCT02985554
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Chicago
Acute Myeloid Leukemia (AML), MLL Rearrangement
Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
The goal of this observational study is to learn about the predict value of leukemia stem cell for acute myeloid leukemia patients with MLL-rearrangement.
- Trial name
- MLL-LSC (NCT07537738)
- Testing
- Detection of leukemia stem cell using multiparameter flow cytometry
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Peking University People's Hospital
MDS, SCT
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
This study aims to develop highly sensitive methods for early detection of relapse based on the patients unique mutations. Initially, a mutational screen is being performed.
- Conditions
- MDS, SCT, MRD
- Trial name
- NCT02872662
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 308 people
- Sponsor
- Nordic MDS Group
AL Amyloidosis
Allo SCT in Amyloidosis Non-interventional Study
Light-chain (AL-) amyloidosis is a very rare monoclonal plasma cell disorder with poor prognosis. Rarity of disease has precluded performance of randomized controlled trials comparing various possible treatment modalities.
- Trial name
- NCT02257905
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Acute Myeloid Leukemia, Myelodysplasia
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT
This study will evaluate a new maintenance therapy with the aim of improving the outcome of patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) after stem cell transplantation.
- Trial name
- AMADEUS (NCT04173533)
- Testing
- Oral azacitidine
- Where
- 20 sites in United Kingdom
- Volunteers
- 326 people
- Sponsor
- University of Birmingham
Leukemia, Lymphoma
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002989
- Testing
- busulfan, cyclophosphamide, idarubicin
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 207 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
The purpose of this study was to confirm a safe dose and schedule as well as the preliminary efficacy of siremadlin alone, and in combination with donor lymphocyte infusion (DLI), in adult participants with Acute Myeloid Leukemia…
- Trial name
- NCT05447663
- Testing
- Siremadlin
- Where
- 6 sites in Germany, Italy and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Sickle Cell Anemia, Hemoglobinopathy
Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
The major goal of this study is to determine the risks and benefits of stem cell transplants in combination with a newer, less toxic conditioning chemotherapy treatment in patients with severe sickle cell disease (SCD) or sickle…
- Conditions
- Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
- Trial name
- NCT00040417
- Testing
- FLUDARABINE, CAMPATH-IH, Total Body Irradiation
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
This is a prospective, open label, single arm, multi-centre phase II trial aiming to evaluate the safety and efficacy of Enasidenib (investigational product) as prophylactic consolidation in patients with IDH2-mutated MDS, CMML…
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation
- Trial name
- NCT04522895
- Testing
- Enasidenib
- Where
- 11 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Myelodysplastic Syndromes, Acute Myeloid Leukemia
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation
High risk MDS (Myelodysplastic Syndrome) patients will be treated with SGI-110 after Allogeneic Stem Cell Transplantation in the hypothesis that SGI-110 maintenance given early after HSCT can prevent relapse without increasing…
- Trial name
- NCT03454984
- Testing
- Guadecitabine
- Where
- 12 sites in France
- Volunteers
- 40 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Leukemia, Myeloid, Acute
Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients
Recent advances in acute myeloid leukemia (AML) have been characterized by a better understanding of disease biology. As such, FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) have been recognized as conferring a…
- Trial name
- PONALLO (NCT03690115)
- Testing
- Ponatinib 30 MG
- Where
- 14 sites in France
- Volunteers
- 23 people
- Sponsor
- Versailles Hospital
Acute Myeloid Leukemia
Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial
To better delineate the contribution of VEN-DEC to the treatment of AML patients aged between ≥ 60 and < 75 years and deemed fit for Allo-HSCT, real-world data on a patient-level basis will be collected and utilized to generate a…
- Trial name
- VenDec-AI (NCT07420790)
- Where
- Italy
- Volunteers
- 1,941 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia